Hi friends,
I just posted on my blog the last of my ASH 2013 video interviews namely ASH 2013: Dr. Byrd on the New Data on Ibrutinib and Obinutuzumub in CLL.
We go into some detail, especially about obinutuzumab.
Brian
ASH 2013: Dr. Byrd on the New Data on Ibrutini... - CLL Support
ASH 2013: Dr. Byrd on the New Data on Ibrutinib and Obinutuzumub in CLL.
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
ASH 2013: Dr. John Pagel Speculates on the Future of CLL Therapies including the late breaking data on Idelalisib
ASH 2013: Dr. John Pagel Speculates on the Future of CLL (chronic lymphocytic leukemia) Therapies...
ASH 2016: Dr. Mato on real world data on ibrutinib
Hi,
This week I'm posting an interview that I had with Dr. Anthony Mato from U Penn when we talked...
ASH 2013: INTERVIEW WITH DR. FURMAN RE: IDELALISIB
Hi friends
In my last blog post ( http://bkoffman.blogspot.com ), I have a short and interesting...
ASH 2013: Dr. John Pagel Discusses Radio-Immune Therapy (RIT) in Chronic Lymphocytic Leukemia (CLL)
Friends
In another interview from ASH 2013 that I just posted on my blog...
ASCO 2014: Dr. Susan O'Brien Reviews the 3 years follow-up Data on Ibrutinib in CLL
Friends,
I am stuck at the airport on my way to OSU waiting for my delayed flight, so I thought I...
Related Posts
- ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.
- ASH 2018: Dr. Lindsey Roeker research from ASH 2018 on real world use of venetoclax for CLL
ASH 2018: Professor Peter Hillmen on the Combination of Ibrutinib and Obinutuzumab in CLL: Timing Matters
ASH 2017: Dr. Richard Furman on the importance of MCL-1 in CLL (chronic lymphocytic leukemia)- ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance
